FDA Green Lights Expanded Access to Pancreatic Cancer Drug, Daraxonrasib MedNews
MONDAY, May 4, 2026 The U.S. Food and Drug Administration (FDA) granted expanded access for the use of an experimental pancreatic cancer drug, daraxonrasib.This